505 Relationship of infusion duration and dose to safety, efficacy and pharmacodynamics: second part of a phase 1–2 study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors

• Manish Patel,
• Melissa Johnson,
• James Strauss,
• Timothy Cripe,
• Erol Wiegert,
• Monica Reckner,
• Alice Bexon,
• Kah-Whye Peng,
• Stephen Russell,
• Luke Russell,
• Jaime Merchan

Affiliations

Manish Patel

General Medicine, University Hospital Wishaw, Wishaw, UK

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

James Strauss

2Mary Crowley Cancer Research Center, Dallas, TX, USA

Timothy Cripe

5Nationwide Children’s Hospital, Columbus, OH, USA

Erol Wiegert

8Bexon Clinical Consulting, Upper Montclair, USA

Monica Reckner

5Vyriad, Inc., Rochester, MN, USA

Alice Bexon

7Vyriad Inc., Rochester, MN, USA

Kah-Whye Peng

6Vyriad Inc. and Mayo Clinic, Rochester, MN, USA

Stephen Russell

6Vyriad Inc. and Mayo Clinic, Rochester, MN, USA

Luke Russell

7Vyriad Inc., Rochetsre, MN, USA

Jaime Merchan

9University of Miami, Miami, FL, USA